Developing a novel antifungal targeting GWT1 for the treatment of invasive aspergillosis and rare mold infections
Ended Project Grant Awarded Last action
- Award ID
- R44AI131864
- Recipient
-
Amplyx Pharmaceuticals, Inc. UEI N4A8X52DCND5 Part of Pfizer Inc.
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,457,638
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- California, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$18,156 | |
| Amendment | $0 | |
| Amendment | $725,501 | |
| Original award | $750,293 |
Quick answers
Who received award R44AI131864?
R44AI131864 was awarded to Amplyx Pharmaceuticals, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 18, 2017.
How much is award R44AI131864 worth?
$1,457,638 has been obligated on R44AI131864.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award